WILLIAMS-LEA
2.6.2014 10:01:48 CEST | Business Wire | Pressemeddelelse
Williams Lea has appointed Dan Ellerton as the new Williams Lea Group CEO, effective 1 June.
Ellerton will be based in the UK and has global responsibility for the Group, including Williams Lea, Tag and the Group’s other branded businesses.
Williams Lea is a global leader in providing specialist Business Process Outsourcing services to support organizational transformation through re-engineering processes, deploying technologies and highly experienced collaborative teams to improve client efficiency and cost reduction. Tag, a leading brand services agency, works with global brands to implement effective marketing communications consistently across all media and markets through the smart centralization of their production.
Ellerton is appointed from the Group’s owner Deutsche Post DHL. His appointment indicates the ongoing commitment to leverage the Deutsche Post DHL client base and solutions to support maintaining market leadership for the Williams Lea businesses.
Continuing his exceptional career with Deutsche Post DHL over 24 years, Ellerton will bring focus to growth across the Williams Lea Group. Williams Lea has recently completed strategic growth plans for both its businesses and, following the acquisition of Tag, invested in the launch of a fully integrated brand services offering as well as a revitalised brand during 2013. Clear market opportunity combined with these and other investments provide a solid foundation for further success.
Ellerton has excelled in leading growth in his previous roles as DHL Supply Chain’s Chief Development Officer and leader of the Global Specialist Businesses. He has also held key operational leadership roles heading up DHL Supply Chain’s business in Mainland Europe, the UK, Middle East and Africa.
“Dan has been pivotal to Deutsche Post DHL’s success during the past two decades and, in this new role, we are looking for him to grow our Williams Lea Group businesses and bring those unique propositions and offerings to the marketplace while leveraging the wider Group’s skills to continue to strengthen its performance and scale its operations,” says John Gilbert, Member of the Board of Management, CEO Supply Chain.
About Williams Lea:
Williams Lea is a leading global BPO organization. We specialise in Corporate Information Solutions that re-engineer end-to-end business processes. We combine consultancy, unique expertise and the latest integrated technology to develop solutions that transform the way organizations communicate and exchange their printed and electronic information. Williams Lea has a proven track record of enabling its clients to improve the delivery of their customer communications – allowing them to focus on their core business whilst enjoying the benefits of improved efficiency and control, reduced costs and an enhanced customer experience across the marketing supply chain.
The Williams Lea Group also encompasses subsidiaries Tag, a brand services agency that manages and implements global communications campaigns, and TSO, the leading provider of publishing solutions to the UK public sector. Tag clients – over 47 of the world’s top 500 brands across more than 120 different countries – trust us to bring control and consistency to their campaigns, taking them to market quickly and effectively. With over 2000 employees globally, Tag’s experience and scale allows our client base of over 120,000 marketers to focus on realizing the potential of their brands.
The Group employs approximately 11,500 staff across the globe, with key locations in the Americas, EMEA and Asia Pacific and is owned by Deutsche Post DHL We work with many of the world’s most respected brands in sectors such as financial services, life sciences, legal, retail, FMCG, apparel, investment banking, automotive and public sectors. For more information, visit www.williamslea.com .
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140602005402/en/
Contact:
Williams Lea EMEA
Louise Barber, +44 (0)787 2066 260
Marketing
Director
louise.barber@williamslea.com
or
Williams
Lea Americas
Michelle Bodick, (212) 351-9036
Vice President of
Marketing
michelle.bodick@williamslea.com
or
Williams
Lea Asia Pacific
Hina Kotecha, +852 2890 0930
Marketing
Director
hina.kotecha@williamslea.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum